Deubiquitinases in cancer: new functions and therapeutic options
- PMID: 21996736
- DOI: 10.1038/onc.2011.443
Deubiquitinases in cancer: new functions and therapeutic options
Abstract
Deubiquitinases (DUBs) have fundamental roles in the ubiquitin system through their ability to specifically deconjugate ubiquitin from _targeted proteins. The human genome encodes at least 98 DUBs, which can be grouped into 6 families, reflecting the need for specificity in their function. The activity of these enzymes affects the turnover rate, activation, recycling and localization of multiple proteins, which in turn is essential for cell homeostasis, protein stability and a wide range of signaling pathways. Consistent with this, altered DUB function has been related to several diseases, including cancer. Thus, multiple DUBs have been classified as oncogenes or tumor suppressors because of their regulatory functions on the activity of other proteins involved in tumor development. Therefore, recent studies have focused on pharmacological intervention on DUB activity as a rationale to search for novel anticancer drugs. This strategy may benefit from our current knowledge of the physiological regulatory mechanisms of these enzymes and the fact that growth of several tumors depends on the normal activity of certain DUBs. Further understanding of these processes may provide answers to multiple remaining questions on DUB functions and lead to the development of DUB-_targeting strategies to expand the repertoire of molecular therapies against cancer.
Similar articles
-
Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. doi: 10.1517/13543776.2015.1056737. Epub 2015 Jun 16. Expert Opin Ther Pat. 2015. PMID: 26077642 Free PMC article. Review.
-
Proteasome deubiquitinases as novel _targets for cancer therapy.Int J Biochem Cell Biol. 2012 Nov;44(11):1729-38. doi: 10.1016/j.biocel.2012.07.011. Epub 2012 Jul 20. Int J Biochem Cell Biol. 2012. PMID: 22819849 Review.
-
Deubiquitinase inhibition as a cancer therapeutic strategy.Pharmacol Ther. 2015 Mar;147:32-54. doi: 10.1016/j.pharmthera.2014.11.002. Epub 2014 Nov 6. Pharmacol Ther. 2015. PMID: 25444757 Review.
-
Molecular pathways: translational potential of deubiquitinases as drug _targets.Clin Cancer Res. 2014 Aug 1;20(15):3908-14. doi: 10.1158/1078-0432.CCR-14-0568. Clin Cancer Res. 2014. PMID: 25085788 Review.
-
Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.Cancer Metastasis Rev. 2017 Dec;36(4):655-668. doi: 10.1007/s10555-017-9701-1. Cancer Metastasis Rev. 2017. PMID: 29039082 Free PMC article. Review.
Cited by
-
Potential roles of UCH family deubiquitinases in tumorigenesis and chemical inhibitors developed against them.Am J Cancer Res. 2024 Jun 15;14(6):2666-2694. doi: 10.62347/OEGE2648. eCollection 2024. Am J Cancer Res. 2024. PMID: 39005671 Free PMC article. Review.
-
Cezanne regulates E2F1-dependent HIF2α expression.J Cell Sci. 2015 Aug 15;128(16):3082-93. doi: 10.1242/jcs.168864. Epub 2015 Jul 6. J Cell Sci. 2015. PMID: 26148512 Free PMC article.
-
K63-linked ubiquitination in kinase activation and cancer.Front Oncol. 2012 Jan 31;2:5. doi: 10.3389/fonc.2012.00005. eCollection 2012. Front Oncol. 2012. PMID: 22649774 Free PMC article.
-
USP5 Promotes Uterine Corpus Endometrial Carcinoma Cell Growth and Migration via mTOR/4EBP1 Activation.Cancer Manag Res. 2021 May 13;13:3913-3924. doi: 10.2147/CMAR.S290467. eCollection 2021. Cancer Manag Res. 2021. PMID: 34012297 Free PMC article.
-
Structural and Functional Basis of JAMM Deubiquitinating Enzymes in Disease.Biomolecules. 2022 Jun 29;12(7):910. doi: 10.3390/biom12070910. Biomolecules. 2022. PMID: 35883466 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources